<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id><journal-title-group><journal-title>Investigational New Drugs</journal-title></journal-title-group><issn pub-type="ppub">0167-6997</issn><issn pub-type="epub">1573-0646</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28389981</article-id><article-id pub-id-type="pmc">5443850</article-id><article-id pub-id-type="publisher-id">455</article-id><article-id pub-id-type="doi">10.1007/s10637-017-0455-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fu</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hirte</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Welch</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ilenchuk</surname><given-names>T. T.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lutes</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fields</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nemet</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Dugourd</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Piha-Paul</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Subbiah</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Stewart</surname><given-names>J. M.</given-names></name><address><email>jstewart@soricimed.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution/><institution>Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0408 1469</institution-id><institution-id institution-id-type="GRID">grid.477522.1</institution-id><institution/><institution>Juravinski Cancer Centre, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9132 1600</institution-id><institution-id institution-id-type="GRID">grid.412745.1</institution-id><institution/><institution>London Health Sciences Centre, </institution></institution-wrap>London, ON Canada </aff><aff id="Aff4"><label>4</label>Soricimed Biopharma Inc., Moncton, NB Canada </aff><aff id="Aff5"><label>5</label>Sagecon Inc., Oakville, ON Canada </aff><aff id="Aff6"><label>6</label>CLINSIG Research Consulting Inc., Brampton, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>35</volume><issue>3</issue><fpage>397</fpage><lpage>397</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media New York 2017</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d29e87" ext-link-type="doi" xlink:href="10.1007/s10637-017-0438-z"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media New York 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>Erratum to: Invest New Drugs</bold>
</p><p>
<bold>DOI 10.1007/s10637-017-0438-z</bold>
</p><p>The article First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors, written by S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, and J. M. Stewart, was originally published electronically on the publisher&#x02019;s internet portal (currently SpringerLink) on 01 February 2017 without open access.</p><p>With the author(s)&#x02019; decision to opt for Open Choice the copyright of the article changed on 05 April 2017 to &#x000a9; The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.</p></body><back><fn-group><fn><p>The online version of the original article can be found at doi: 10.1007/s10637-017-0438-z
</p></fn></fn-group></back></article>